Skip to main content
Journal Guides6 min readUpdated Oct 11, 2026

Nature Biotechnology SJR and Scopus Metrics: What They Actually Mean

Nature Biotechnology still has extraordinary cross-field metrics, but the real submission question is whether your paper is truly technology-first enough for that room.

By Manusights Editorial Team•
Editorial processThe Manusights editorial team researches and maintains these guides using source review, field-specific analysis, and our documented editorial process.How we work

Next step

Choose the next useful decision step first.

Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.

Open Journal Fit ChecklistPrivate API processing. Your manuscript is not used to train models.Run Free Readiness Scan

Quick answer: Nature Biotechnology still has extraordinary Scopus authority across biotechnology and adjacent fields. Nature Biotechnology's own journal metrics page (read October 2026) prints a 2025 SJR of 23.109 and SNIP of 8.129. Scopus-based aggregator sources place the 2024 figures at SJR 19.006, impact score 14.83, global rank 18, and h-index 531. That confirms genuine cross-field flagship influence.

The hard submission question is not whether the journal is strong. It is whether the manuscript is truly an enabling-technology story rather than a strong biology paper with a technical wrapper.

Direct answer

If your question is whether Nature Biotechnology still behaves like a top biotechnology flagship in the Scopus system, the answer is yes.

Metric
Current value
What it tells you
SJR
23.109 (2025, per Nature Biotechnology)
prestige-weighted influence remains exceptional across multiple categories
Impact Score
14.83 (2024)
citation density is still very high even after recent cooling from the 2021-2022 peak
Global rank
18 (2024)
the journal sits near the top of the full global ranking
h-index
531 (2024)
the archive has deep long-run biotechnology influence
Best quartile
Q1
the title remains firmly top-tier
Coverage history
1989-2025
this is durable flagship authority, not a short-lived spike

That profile matters because Nature Biotechnology is one of the few journals whose influence clearly travels across biotechnology, bioengineering, biomedicine, and translational platform work.

Overview

The useful summary is that Nature Biotechnology remains in the cross-field flagship lane, but the current 2024 profile is below its 2021-2022 peak. The current Resurchify-based impact score is 14.83, with SJR still an extraordinary 19.006. That still describes a journal of exceptional strength.

It just means authors should stop leaning on stale number sets. For the broader fit picture, see our Nature Biotechnology journal profile.

What changed in 2024

The 2024 picture is stronger than 2023 on prestige weighting, but still below the earlier peak.

  • SJR moved up from 18.117 in 2023 to 19.006 in 2024
  • impact score moved up from 13.24 to 14.83
  • global rank held at 18

That matters because it confirms the journal remains firmly in the same elite band. For authors, the implication is that the editorial identity question matters more than the raw prestige question.

Ten-year SJR and Scopus trend

Year
SJR
Impact Score
Global Rank
2024
19.006
14.83
18
2023
18.117
13.24
18
2022
22.781
16.35
8
2021
20.120
20.67
14
2020
15.358
14.92
32
2019
12.565
10.50
47
2018
14.568
10.55
36
2017
18.252
12.37
23
2016
20.666
13.97
15
2015
18.263
14.52
20
2014
16.609
12.68
24

The trend shows a journal that has stayed at extraordinary levels for a decade, with some fluctuation in short-window citation density but persistent flagship prestige weighting.

What the trend means in practice

For authors, the trend usually means:

  • the journal still expects platform or enabling-technology consequence
  • broad usability matters more than a narrow technical flourish
  • strong biology alone is not enough if the technology does not travel
  • the archive is strong enough that weak benchmarking or narrow utility gets exposed quickly

That is why technically polished but adoption-thin papers still miss here.

How Nature Biotechnology compares with realistic neighbors

Journal
Relative 2024 profile
What the metric profile usually signals
Nature Biotechnology
SJR 19.006
flagship cross-field technology journal
Nature Methods
adjacent methods flagship
better when the paper is pure method rather than broader biotech platform
Nature Medicine
different flagship lane
stronger for disease-consequence and translational medicine than enabling technology
specialist technology journals
materially lower prestige concentration
better fit when utility is narrower or audience is more technical

This is the useful comparison. Nature Biotechnology is strongest when the technology, utility, and adoption logic are the story.

What editors are really screening for

The official aims page is unusually clear:

  • new concepts in technology and methodology
  • relevance to biological, biomedical, agricultural, and environmental sciences
  • broad scope across multiple biotechnology lanes
  • work that reaches the widest possible audience

That is why the metric profile stays so strong. The journal is not only selecting for novelty. It is selecting for technologies that travel.

What we see in Nature Biotechnology Metric Questions

For Nature Biotechnology metric questions, three mistakes recur.

The biology-first mistake. Authors often target the journal with strong biology papers whose technical component is not actually the central reason the paper matters.

The weak-benchmark mistake. Another common miss is an appealing platform paper that still lacks benchmarking strong enough to support broad utility claims.

The narrow-tool mistake. We also see submissions built around a tool or modality whose usable audience is too small for the way the manuscript is framed. The SJR confirms authority. It does not rescue a narrow adoption story.

That is the practical value of the metrics. They explain why the journal can be brutally selective about manuscript identity.

What these metrics mean for authors

For authors, the current profile says:

  • publication here still carries major signal across biotechnology and translational platform work
  • the archive is deep enough that weak utility logic becomes obvious quickly
  • broad usability matters more than technical cleverness alone
  • if the manuscript truly fits, the visibility upside is enormous

The h-index of 531 matters because it reflects a deep archive of technologies and platforms that other fields actually reused.

Submit If / Think Twice If

Submit if:

  • the manuscript is clearly technology first
  • the benchmark story is strong on first read
  • the utility extends beyond one narrow use case
  • the audience plausibly spans multiple biotech or biomedical communities

Think twice if:

  • the paper is mainly a biology story with a technical component
  • the platform claim depends on limited or soft benchmarking
  • the likely audience is smaller than the framing suggests
  • a narrower methods or specialty journal is the honest fit

Readiness check

Run the scan while the topic is in front of you.

See score, top issues, and journal-fit signals before you submit.

Get free manuscript previewPrivate API processing. Your manuscript is not used to train models.See example reports

What should drive the decision after the metrics check

The better question is whether the manuscript is truly a Nature Biotechnology paper in its current form.

That is why the next useful reads are:

  • Nature Biotechnology journal profile

If the manuscript is genuinely enabling-technology first, the upside is enormous. If it is still mostly biology with a technical wrapper, the metrics are mostly a warning against over-targeting. A Nature Biotechnology submission framing check is a direct way to pressure-test that before submission.

Practical verdict

Nature Biotechnology still has a genuine flagship Scopus profile across biotechnology and related fields, and the 2024 numbers confirm it remains in that rare band.

For authors, the metric question is already settled. The live question is whether the manuscript has enough technology identity and broad utility for the readership the journal actually serves.

  1. Nature Biotechnology JIF, Manusights.

Frequently asked questions

Nature Biotechnology's own journal metrics page (read October 2026) prints a 2025 SJR of 23.109, and Scopus-based aggregators put the 2024 SJR at 19.006. Either keeps it near the very top of biotechnology-related journals.

Current Scopus-based sources place Nature Biotechnology's 2024 impact score at 14.83, with a global rank of 18 and h-index of 531.

Because it remains one of the central journals for enabling technologies, platforms, and methods that travel across biotechnology, medicine, and engineering.

No. The real question is whether the manuscript is truly technology-first, broadly useful, and benchmarked strongly enough for the journal.

References

Sources

  1. 1. Nature Biotechnology metrics page, Resurchify.
  2. 2. Nature Biotechnology Aims & Scope, Nature Portfolio.
  3. 3. Nature Biotechnology submission guidelines, Nature Portfolio.

Before you upload

Choose the next useful decision step first.

Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.

Use the scan once the manuscript and target journal are concrete enough to evaluate.

Private API processing. Your manuscript is not used to train models.

Open Journal Fit ChecklistRun Free Readiness Scan

Put the guidance to work

Choose the practical next step for your research.

Start with the question in front of you, or use the guided learning path when you want a clearer view of the full publishing process.

Find my next step Choose a research stage or a specific kind of help.Learn in Academy Follow a guided path through the publishing process.
Internal navigation

Where to go next

Start here

Same journal, next question

Browse this topic

Supporting reads

Conversion step

Back to all articles